3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Breast Neoplasms
6
Triple Negative Breast Neoplasms
3
Recurrence
3
Prostatic Neoplasms
3
Urinary Bladder Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Turcot syndrome
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Myeloma
1
Mucopolysaccharidosis I
1
Mesothelioma, Malignant
1
Lymphoma, T-Cell, Peripheral
1
Liposarcoma
1
Inhibition of Autophagy Synergizes Anti-tumor Effect
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Genetic Diseases, Inborn
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esophageal Squamous Cell Carcinoma
1
Interventions
Magnetic Resonance Spectroscopy
17
Iodine-131
16
lenvatinib
13
trametinib
12
Thyrotropin Alfa
11
Sorafenib
11
pembrolizumab
10
dabrafenib
10
Paclitaxel
9
vandetanib
8
Thyroxine
8
Surgical Procedures, Operative
7
Sunitinib
7
selpercatinib
6
cabozantinib
6
Nivolumab
6
Fluorodeoxyglucose F18
6
Everolimus
6
pazopanib
5
Vemurafenib
5
Thyroidectomy
5
Specimen Handling
5
Saline Solution
5
Radiotherapy
5
Radiofrequency Ablation
5
Cyclophosphamide
5
Cisplatin
5
Biopsy
5
apatinib
4
anlotinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Thyroid Neoplasms
×
Clinical Trials, Phase II as Topic
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled